Serum markers to monitor response to zoledronic acid in patients with bone metastases from breast cancer.

被引：0
|
作者：
Mercatali, L.
Ibrahim, T.
Sacanna, E.
Ricci, R.
Scarpi, E.
Fabbri, F.
Serra, P.
Tison, C.
Amadori, D.
机构：
[1] Osteooncol Ctr, Meldola, Italy
[2] IRST, Meldola, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.1105
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1105
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase III trial of oral ibandronate and intravenous zoledronic acid in breast cancer patients with bone metastases:: comparison of bone turnover markers
    Lichinitser, M.
    Coleman, R. E.
    Tjulandin, S. A.
    Bergstrom, B.
    Body, J.-J.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 113 - 113
  • [22] Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane
    Martinetti, A
    Bajetta, E
    Seregni, E
    Zilembo, N
    Ferrari, L
    Noberasco, C
    Massaron, S
    Rimassa, L
    Bombardieri, E
    [J]. TUMOR BIOLOGY, 1997, 18 (04) : 197 - 205
  • [23] Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases
    Body, J.-J.
    Lichinitser, M.
    Tjulandin, S.
    Garnero, P.
    Bergstroem, B.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (07) : 1165 - 1171
  • [24] Zoledronic acid and atrial fibrillation in cancer patients with bone metastases
    Aksoy, S.
    Dizdar, O.
    Turgut, D.
    Dede, D. Sener
    Arslan, C.
    Harputluoglu, H.
    Altundag, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases
    Tas, Faruk
    Duranyildiz, Derya
    Oguz, Hilal
    Camlica, Hakan
    Yasasever, Vildan
    Topuz, Erkan
    [J]. MEDICAL ONCOLOGY, 2008, 25 (03) : 346 - 349
  • [26] Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases
    Faruk Tas
    Derya Duranyildiz
    Hilal Oguz
    Hakan Camlica
    Vildan Yasasever
    Erkan Topuz
    [J]. Medical Oncology, 2008, 25 : 346 - 349
  • [27] Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid
    Coleman, RE
    Major, P
    Lipton, A
    Brown, JE
    Lee, KA
    Smith, M
    Saad, F
    Zheng, M
    Hei, YJ
    Seaman, J
    Cook, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) : 4925 - 4935
  • [28] Zoledronic acid compared with pamidronate in patients with prostate cancer and bone metastases: Effects on skeletal complications and bone markers
    不详
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 57 - 57
  • [29] Zoledronic acid reduces bone resorption markers in patients with lytic and blastic bone metastases
    Saad, F
    Gleason, D
    Rosen, L
    Gordon, D
    [J]. BONE, 2002, 30 (03) : 53S - 53S
  • [30] Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases
    Chen, TL
    Berenson, J
    Vescio, R
    Swift, R
    Gilchick, A
    Goodin, S
    LoRusso, P
    Ma, PM
    Ravera, C
    Deckert, F
    Schran, H
    Seaman, J
    Skerjanec, A
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (11): : 1228 - 1236
12345